(RVTY) Revvity - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US7140461093
Stock: Instruments, Reagents, Software, Sequencing, Diagnostics
Total Rating 44
Risk 78
Buy Signal -0.12
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.29% |
| Yield on Cost 5y | 0.24% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 96.1% |
| Payout Ratio | 6.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 37.7% |
| Relative Tail Risk | -8.12% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.31 |
| Alpha | -34.21 |
| Character TTM | |
|---|---|
| Beta | 1.158 |
| Beta Downside | 0.956 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.72% |
| CAGR/Max DD | -0.22 |
Description: RVTY Revvity January 04, 2026
Revvity Inc. (NYSE: RVTY) is a diversified health-sciences company that supplies a broad portfolio of instruments, reagents, software, and services for genetic-disorder screening, infectious-disease diagnostics, and oncology-focused genomic workflows. Its offerings span from DNA-sequencing kits and immunodiagnostic platforms (e.g., AutoDELFIA, EUROIMMUN) to laboratory automation and data-management tools that support pharmaceutical, academic, and public-health customers worldwide.
Key metrics (FY 2023): revenue of roughly $2.1 billion, operating margin around 12 %, and R&D spending near 8 % of sales-levels that align with the industry’s emphasis on rapid assay development. The life-sciences tools sector is being driven by a projected 12 % CAGR in next-generation sequencing (NGS) spend through 2029 and by rising demand for point-of-care genetic tests, both of which should sustain Revvity’s growth in high-margin software and subscription services.
For a deeper quantitative view, explore ValueRay’s Revvity valuation model to see how these trends translate into forward-looking price targets.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 241.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.17 > 1.0 |
| NWC/Revenue: 31.81% < 20% (prev 61.58%; Δ -29.77% < -1%) |
| CFO/TA 0.05 > 3% & CFO 584.3m > Net Income 241.7m |
| Net Debt (2.60b) to EBITDA (765.8m): 3.39 < 3 |
| Current Ratio: 1.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (113.2m) vs 12m ago -6.88% < -2% |
| Gross Margin: 50.16% > 18% (prev 0.54%; Δ 4962 % > 0.5%) |
| Asset Turnover: 23.26% > 50% (prev 22.23%; Δ 1.03% > 0%) |
| Interest Coverage Ratio: 3.91 > 6 (EBITDA TTM 765.8m / Interest Expense TTM 92.2m) |
Altman Z'' 3.83
| A: 0.07 (Total Current Assets 2.24b - Total Current Liabilities 1.33b) / Total Assets 12.17b |
| B: 0.49 (Retained Earnings 5.96b / Total Assets 12.17b) |
| C: 0.03 (EBIT TTM 360.5m / Avg Total Assets 12.28b) |
| D: 1.47 (Book Value of Equity 7.25b / Total Liabilities 4.92b) |
| Altman-Z'' Score: 3.83 = AA |
Beneish M -2.85
| DSRI: 1.14 (Receivables 744.7m/632.4m, Revenue 2.86b/2.76b) |
| GMI: 1.07 (GM 50.16% / 53.90%) |
| AQI: 1.01 (AQ_t 0.76 / AQ_t-1 0.76) |
| SGI: 1.04 (Revenue 2.86b / 2.76b) |
| TATA: -0.03 (NI 241.7m - CFO 584.3m) / TA 12.17b) |
| Beneish M-Score: -2.85 (Cap -4..+1) = A |
What is the price of RVTY shares?
As of February 07, 2026, the stock is trading at USD 101.59 with a total of 1,462,159 shares traded.
Over the past week, the price has changed by -6.63%, over one month by -3.23%, over three months by +13.55% and over the past year by -14.50%.
Over the past week, the price has changed by -6.63%, over one month by -3.23%, over three months by +13.55% and over the past year by -14.50%.
Is RVTY a buy, sell or hold?
Revvity has received a consensus analysts rating of 4.16.
Therefore, it is recommended to buy RVTY.
- StrongBuy: 10
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RVTY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 119.6 | 17.7% |
| Analysts Target Price | 119.6 | 17.7% |
| ValueRay Target Price | 103.2 | 1.5% |
RVTY Fundamental Data Overview February 07, 2026
P/E Trailing = 48.3107
P/E Forward = 18.797
P/S = 4.0446
P/B = 1.6236
P/EG = 0.6199
Revenue TTM = 2.86b USD
EBIT TTM = 360.5m USD
EBITDA TTM = 765.8m USD
Long Term Debt = 2.63b USD (from longTermDebt, two quarters ago)
Short Term Debt = 588.8m USD (from shortTermDebt, last quarter)
Debt = 3.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.60b USD (from netDebt column, last quarter)
Enterprise Value = 14.15b USD (11.55b + Debt 3.52b - CCE 919.9m)
Interest Coverage Ratio = 3.91 (Ebit TTM 360.5m / Interest Expense TTM 92.2m)
EV/FCF = 27.70x (Enterprise Value 14.15b / FCF TTM 510.8m)
FCF Yield = 3.61% (FCF TTM 510.8m / Enterprise Value 14.15b)
FCF Margin = 17.89% (FCF TTM 510.8m / Revenue TTM 2.86b)
Net Margin = 8.46% (Net Income TTM 241.7m / Revenue TTM 2.86b)
Gross Margin = 50.16% ((Revenue TTM 2.86b - Cost of Revenue TTM 1.42b) / Revenue TTM)
Gross Margin QoQ = 43.80% (prev 53.60%)
Tobins Q-Ratio = 1.16 (Enterprise Value 14.15b / Total Assets 12.17b)
Interest Expense / Debt = 0.67% (Interest Expense 23.5m / Debt 3.52b)
Taxrate = 9.62% (25.8m / 268.3m)
NOPAT = 325.8m (EBIT 360.5m * (1 - 9.62%))
Current Ratio = 1.68 (Total Current Assets 2.24b / Total Current Liabilities 1.33b)
Debt / Equity = 0.48 (Debt 3.52b / totalStockholderEquity, last quarter 7.25b)
Debt / EBITDA = 3.39 (Net Debt 2.60b / EBITDA 765.8m)
Debt / FCF = 5.08 (Net Debt 2.60b / FCF TTM 510.8m)
Total Stockholder Equity = 7.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.97% (Net Income 241.7m / Total Assets 12.17b)
RoE = 3.24% (Net Income TTM 241.7m / Total Stockholder Equity 7.45b)
RoCE = 3.57% (EBIT 360.5m / Capital Employed (Equity 7.45b + L.T.Debt 2.63b))
RoIC = 3.04% (NOPAT 325.8m / Invested Capital 10.72b)
WACC = 7.95% (E(11.55b)/V(15.07b) * Re(10.18%) + D(3.52b)/V(15.07b) * Rd(0.67%) * (1-Tc(0.10)))
Discount Rate = 10.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.23%
[DCF Debug] Terminal Value 70.82% ; FCFF base≈523.1m ; Y1≈348.7m ; Y5≈164.1m
Fair Price DCF = 5.53 (EV 3.22b - Net Debt 2.60b = Equity 627.1m / Shares 113.4m; r=7.95% [WACC]; 5y FCF grow -38.89% → 2.90% )
EPS Correlation: -56.44 | EPS CAGR: -8.89% | SUE: 1.65 | # QB: 1
Revenue Correlation: -45.82 | Revenue CAGR: -5.73% | SUE: 1.39 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.02 | Chg30d=-0.091 | Revisions Net=-1 | Analysts=16
EPS current Year (2026-12-31): EPS=5.41 | Chg30d=+0.106 | Revisions Net=+3 | Growth EPS=+6.9% | Growth Revenue=+4.4%
EPS next Year (2027-12-31): EPS=6.00 | Chg30d=+0.134 | Revisions Net=+3 | Growth EPS=+11.0% | Growth Revenue=+5.1%
P/E Forward = 18.797
P/S = 4.0446
P/B = 1.6236
P/EG = 0.6199
Revenue TTM = 2.86b USD
EBIT TTM = 360.5m USD
EBITDA TTM = 765.8m USD
Long Term Debt = 2.63b USD (from longTermDebt, two quarters ago)
Short Term Debt = 588.8m USD (from shortTermDebt, last quarter)
Debt = 3.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.60b USD (from netDebt column, last quarter)
Enterprise Value = 14.15b USD (11.55b + Debt 3.52b - CCE 919.9m)
Interest Coverage Ratio = 3.91 (Ebit TTM 360.5m / Interest Expense TTM 92.2m)
EV/FCF = 27.70x (Enterprise Value 14.15b / FCF TTM 510.8m)
FCF Yield = 3.61% (FCF TTM 510.8m / Enterprise Value 14.15b)
FCF Margin = 17.89% (FCF TTM 510.8m / Revenue TTM 2.86b)
Net Margin = 8.46% (Net Income TTM 241.7m / Revenue TTM 2.86b)
Gross Margin = 50.16% ((Revenue TTM 2.86b - Cost of Revenue TTM 1.42b) / Revenue TTM)
Gross Margin QoQ = 43.80% (prev 53.60%)
Tobins Q-Ratio = 1.16 (Enterprise Value 14.15b / Total Assets 12.17b)
Interest Expense / Debt = 0.67% (Interest Expense 23.5m / Debt 3.52b)
Taxrate = 9.62% (25.8m / 268.3m)
NOPAT = 325.8m (EBIT 360.5m * (1 - 9.62%))
Current Ratio = 1.68 (Total Current Assets 2.24b / Total Current Liabilities 1.33b)
Debt / Equity = 0.48 (Debt 3.52b / totalStockholderEquity, last quarter 7.25b)
Debt / EBITDA = 3.39 (Net Debt 2.60b / EBITDA 765.8m)
Debt / FCF = 5.08 (Net Debt 2.60b / FCF TTM 510.8m)
Total Stockholder Equity = 7.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.97% (Net Income 241.7m / Total Assets 12.17b)
RoE = 3.24% (Net Income TTM 241.7m / Total Stockholder Equity 7.45b)
RoCE = 3.57% (EBIT 360.5m / Capital Employed (Equity 7.45b + L.T.Debt 2.63b))
RoIC = 3.04% (NOPAT 325.8m / Invested Capital 10.72b)
WACC = 7.95% (E(11.55b)/V(15.07b) * Re(10.18%) + D(3.52b)/V(15.07b) * Rd(0.67%) * (1-Tc(0.10)))
Discount Rate = 10.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.23%
[DCF Debug] Terminal Value 70.82% ; FCFF base≈523.1m ; Y1≈348.7m ; Y5≈164.1m
Fair Price DCF = 5.53 (EV 3.22b - Net Debt 2.60b = Equity 627.1m / Shares 113.4m; r=7.95% [WACC]; 5y FCF grow -38.89% → 2.90% )
EPS Correlation: -56.44 | EPS CAGR: -8.89% | SUE: 1.65 | # QB: 1
Revenue Correlation: -45.82 | Revenue CAGR: -5.73% | SUE: 1.39 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.02 | Chg30d=-0.091 | Revisions Net=-1 | Analysts=16
EPS current Year (2026-12-31): EPS=5.41 | Chg30d=+0.106 | Revisions Net=+3 | Growth EPS=+6.9% | Growth Revenue=+4.4%
EPS next Year (2027-12-31): EPS=6.00 | Chg30d=+0.134 | Revisions Net=+3 | Growth EPS=+11.0% | Growth Revenue=+5.1%